65259-90-7

Basic information

• Product Name: 4-TERT-BUTYL-PHENYLTHIOUREA
• Synonyms: N-[4-(TERT-BUTYL)PHENYL]THIOUREA;4-TERT-BUTYL-PHENYLTHIOUREA
• CAS NO: 65259-90-7
• Molecular Formula: C₁₁H₁₆N₂S
• Molecular Weight: 208.32
• Mol File: 65259-90-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-TERT-BUTYL-PHENYLTHIOUREA(CAS DataBase Reference)
• NIST Chemistry Reference: 4-TERT-BUTYL-PHENYLTHIOUREA(65259-90-7)
• EPA Substance Registry System: 4-TERT-BUTYL-PHENYLTHIOUREA(65259-90-7)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 65259-90-7(Hazardous Substances Data)

Upstream product

• 19241-24-8 4-(tert-butylbenzyl)isothiocyanate 
• 769-92-6 4-tert-Butylaniline 
• 117174-73-9 1-Benzoyl-3-(4-tert-butyl-phenyl)-thiourea 

Downstream Products

• 119125-68-7 N-(4-tert-Butyl-phenyl)-morpholine-4-carboxamidine; hydriodide 
• 119125-47-2 1-(4-tert-Butyl-phenyl)-2-methyl-isothiourea; hydriodide 

Relevant articles and documents

Novel arylimino thiazole compound, preparation method and uses thereof

The present invention relates to a compound with antibacterial synergy activity, a preparation and uses thereof, particularly to a novel arylimino thiazole compound, a preparation method and uses thereof, and specifically discloses a class of compounds represented by a formula (I) or optical isomers, cis-trans isomers or pharmaceutically acceptable salts thereof, a preparation method and uses thereof. The invention further discloses a pharmaceutical composition containing the compound. The compound of the present invention can effectively enhance the antibacterial activity of antibiotics, andcan be used for treating antibiotic-resistant bacteria. The formula (I) is defined in the specification.

Design, synthesis, X-ray crystallographic analysis, and biological evaluation of thiazole derivatives as potent and selective inhibitors of human dihydroorotate dehydrogenase

Human dihydroorotate dehydrogenase (HsDHODH) is a flavin-dependent mitochondrial enzyme that has been certified as a potential therapeutic target for the treatment of rheumatoid arthritis and other autoimmune diseases. On the basis of lead compound 4, which was previously identified as potential HsDHODH inhibitor, a novel series of thiazole derivatives were designed and synthesized. The X-ray complex structures of the promising analogues 12 and 33 confirmed that these inhibitors bind at the putative ubiquinone binding tunnel and guided us to explore more potent inhibitors, such as compounds 44, 46, and 47 which showed double digit nanomolar activities of 26, 18, and 29 nM, respectively. Moreover, 44 presented considerable anti-inflammation effect in vivo and significantly alleviated foot swelling in a dose-dependent manner, which disclosed that thiazole-scaffold analogues can be developed into the drug candidates for the treatment of rheumatoid arthritis by suppressing the bioactivity of HsDHODH.

Improved Procedures for the Preparation of Cycloalkyl-, Arylalkyl-, and Arylthioureas

An improved procedure for the preparation of arylthioureas consists of the reaction of benzoyl isothiocyanate with anilines in acetone and debenzoylation of the resultant N-aryl-N'-benzoylthioureas with 5percent aqueous sodium hydroxide.Bicycloalkylthioureas and N-(arylalkyl)thioureas (e.g. 9H-9-fluorenylthiourea) are directly prepared from the corresponding isothiocyanates and ammonia.